Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SPR | P35270 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456754 | 0.86 | SPR (0.46) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL13476774 | 0.85 | MAPT (0.46) | MAPTPARP1TNKS2PARP2F12 | |
| SCHEMBL21041448 | 0.84 | MAPT (0.44) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL6220992 | 0.83 | MAPT (0.43) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL31128509 | 0.83 | PARP1 (0.44) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL9610905 | 0.79 | MTHFD2 (0.53) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL13250475 | 0.77 | PARP1 (0.51) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL2799009 | 0.77 | MAPT (0.48) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL416000 | 0.77 | ESR2 (0.43) | MAPTPARP1TNKS2PARP2F12 | |
| SCHEMBL28647996 | 0.77 | PARP1 (0.47) | MAPTSPRPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467382-B1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8691827-B2 | Amino tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691827-B2 | Amino tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2434885-B1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120136012-A1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136012-A1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2010138430-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | PDE12, PDE4A, PDE5A | MAPT 1064/4885SPR 468/4885PARP1 1008/4885 |
| US-20120136012-A1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | PDE12, PDE4A, PDE10A | MAPT 1101/4885SPR 315/4885PARP1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.